IRIS
PELLEGRINO, BENEDETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.278
AS - Asia 1.110
EU - Europa 729
SA - Sud America 222
AF - Africa 78
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 3.421
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.233
SG - Singapore 538
CN - Cina 300
IE - Irlanda 187
BR - Brasile 178
IT - Italia 129
SE - Svezia 125
HK - Hong Kong 107
VN - Vietnam 85
DE - Germania 77
ZA - Sudafrica 50
NL - Olanda 43
GB - Regno Unito 30
AT - Austria 25
CA - Canada 24
AR - Argentina 23
FR - Francia 21
FI - Finlandia 16
IN - India 15
RU - Federazione Russa 15
CI - Costa d'Avorio 12
ES - Italia 12
PL - Polonia 12
BE - Belgio 10
CZ - Repubblica Ceca 10
TR - Turchia 10
MX - Messico 9
BD - Bangladesh 8
JP - Giappone 8
EC - Ecuador 6
ID - Indonesia 5
IQ - Iraq 5
AL - Albania 4
CL - Cile 4
UZ - Uzbekistan 4
DO - Repubblica Dominicana 3
EG - Egitto 3
IL - Israele 3
KR - Corea 3
LT - Lituania 3
PK - Pakistan 3
PY - Paraguay 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
A1 - Anonimo 2
BG - Bulgaria 2
CO - Colombia 2
DZ - Algeria 2
GH - Ghana 2
IR - Iran 2
JM - Giamaica 2
KZ - Kazakistan 2
MA - Marocco 2
NG - Nigeria 2
UA - Ucraina 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CH - Svizzera 1
GP - Guadalupe 1
HN - Honduras 1
HU - Ungheria 1
KE - Kenya 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MW - Malawi 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
TM - Turkmenistan 1
TN - Tunisia 1
Totale 3.421
Salva come PNG Salva come JPEG
Città #
Singapore 303
Ashburn 244
Dublin 186
Chandler 179
Santa Clara 110
Hong Kong 106
Beijing 94
Dallas 86
Boardman 63
New York 61
Shanghai 56
Johannesburg 43
Ho Chi Minh City 29
Los Angeles 29
Ann Arbor 23
Princeton 22
São Paulo 22
Vienna 22
Bremen 21
Hefei 20
Hanoi 19
Seattle 18
Frankfurt am Main 17
Munich 17
Parma 14
Dearborn 13
Des Moines 13
Abidjan 12
Helsinki 12
Buffalo 10
Milan 10
Toronto 10
Brooklyn 9
Denver 9
Nuremberg 9
Stockholm 9
Warsaw 9
Ardea 8
Brussels 8
Columbus 8
Montreal 8
Moscow 8
Phoenix 8
Tokyo 8
Wilmington 8
Atlanta 7
Olomouc 7
Ravenna 7
Rio de Janeiro 7
Campinas 6
Reggio Emilia 6
Bologna 5
Falls Church 5
Poplar 5
Rio Saliceto 5
Rome 5
Belo Horizonte 4
Cascina 4
Council Bluffs 4
Jakarta 4
Kunming 4
Nanjing 4
Orem 4
Pavia 4
Shenzhen 4
The Dalles 4
Tirana 4
Turku 4
Amsterdam 3
Ankara 3
Biên Hòa 3
Boston 3
Brasília 3
Buenos Aires 3
Cape Town 3
Charlotte 3
Chennai 3
Fairfield 3
Ha Long 3
Hangzhou 3
Houston 3
Jinan 3
London 3
Manaus 3
Manchester 3
Nanchang 3
Seoul 3
São Bernardo do Campo 3
Tashkent 3
Thái Nguyên 3
Verona 3
Woodbridge 3
Accra 2
Aracaju 2
Augusta 2
Bastia umbra 2
Bexley 2
Bismarck 2
Cabo de Santo Agostinho 2
Capriate San Gervasio 2
Totale 2.194
Salva come PNG Salva come JPEG
Nome #
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 132
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 132
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 131
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 125
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 123
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 123
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 123
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 122
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 121
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 118
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 117
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 115
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 112
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 106
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 101
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 100
A review of immune checkpoint blockade in breast cancer 98
My best choice after a round trip from illness 95
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 89
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 88
A narrative review of the principal glucocorticoids employed in cancer 85
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 84
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 84
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 81
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 80
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? 79
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification 77
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 76
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 71
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies 69
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors 69
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 64
The Innate Immune Microenvironment in Metastatic Breast Cancer 55
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors 55
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study 53
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 53
RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test 44
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making 30
Totale 3.480
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.200
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.200
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202167 0 0 0 0 0 14 15 12 4 6 13 3
2021/202296 1 2 6 7 5 6 7 5 2 8 0 47
2022/2023652 49 66 33 48 70 71 4 47 214 4 38 8
2023/2024335 13 29 6 4 26 74 34 41 13 28 29 38
2024/2025955 36 40 59 52 113 98 53 42 122 87 73 180
2025/20261.250 220 188 258 213 269 102 0 0 0 0 0 0
Totale 3.480